ERCC1 expression in advanced colorectal cancer and matched liver metastases
Research output: Contribution to journal › Journal article › peer-review
Standard
ERCC1 expression in advanced colorectal cancer and matched liver metastases. / Olsen, Lærke Müller; Fiehn, Anne-Marie Kanstrup; Hasselby, Jane Preuss.
In: Pathology, Research and Practice, Vol. 216, No. 3, 152826, 2020.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ERCC1 expression in advanced colorectal cancer and matched liver metastases
AU - Olsen, Lærke Müller
AU - Fiehn, Anne-Marie Kanstrup
AU - Hasselby, Jane Preuss
N1 - Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Platinum-based chemotherapy is part of the standard treatment for patients with colorectal cancer. ERCC1 is a potential predictive biomarker for platinum-based chemotherapy. The aim of this study was to examine interobserver agreement on ERCC1 protein expression in primary colorectal cancer as well as corresponding liver metastasis. Furthermore, comparison of ERCC1-expression in primary tumor and the corresponding liver metastasis was performed.METHODS: Forty patients with primary colorectal cancers and corresponding liver metastases were included. One slide was stained with the anti-ERCC1 antibody, 4F9 clone (DAKO) and evaluated by two gastrointestinal pathology consultants and a pathology registrar separately. Interobserver agreement was evaluated for primary tumors and liver metastases using kappa (κ) statistics. Discordant scorings were reviewed, and consensus was obtained. The expression in primary tumor was compared with the corresponding liver metastases.RESULTS: For the primary tumors agreement was found in 85% of the tumors corresponding to an unweighted kappa value of 0,79 (95% CI 0,64-0,94). For the liver metastases agreement was found in 76% corresponding to an unweighted kappa value of 0,64 (95% CI 0,49-0,79). When comparing primary tumors to the corresponding metastases, no concordance in ERCC1-expression was observed.CONCLUSION: Interobserver agreement of ERCC1 expression was good for both primary tumors and liver metastases, which is crucial for a potential predictive biomarker. As no concordance between primary tumor and liver metastases was found it seems to be of high importance to use tissue from actual tumor burden for evaluation of ERCC1 expression. Further studies and correlation to clinical outcome are warranted.
AB - BACKGROUND: Platinum-based chemotherapy is part of the standard treatment for patients with colorectal cancer. ERCC1 is a potential predictive biomarker for platinum-based chemotherapy. The aim of this study was to examine interobserver agreement on ERCC1 protein expression in primary colorectal cancer as well as corresponding liver metastasis. Furthermore, comparison of ERCC1-expression in primary tumor and the corresponding liver metastasis was performed.METHODS: Forty patients with primary colorectal cancers and corresponding liver metastases were included. One slide was stained with the anti-ERCC1 antibody, 4F9 clone (DAKO) and evaluated by two gastrointestinal pathology consultants and a pathology registrar separately. Interobserver agreement was evaluated for primary tumors and liver metastases using kappa (κ) statistics. Discordant scorings were reviewed, and consensus was obtained. The expression in primary tumor was compared with the corresponding liver metastases.RESULTS: For the primary tumors agreement was found in 85% of the tumors corresponding to an unweighted kappa value of 0,79 (95% CI 0,64-0,94). For the liver metastases agreement was found in 76% corresponding to an unweighted kappa value of 0,64 (95% CI 0,49-0,79). When comparing primary tumors to the corresponding metastases, no concordance in ERCC1-expression was observed.CONCLUSION: Interobserver agreement of ERCC1 expression was good for both primary tumors and liver metastases, which is crucial for a potential predictive biomarker. As no concordance between primary tumor and liver metastases was found it seems to be of high importance to use tissue from actual tumor burden for evaluation of ERCC1 expression. Further studies and correlation to clinical outcome are warranted.
KW - Adenocarcinoma/metabolism
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor/analysis
KW - Colorectal Neoplasms/metabolism
KW - DNA-Binding Proteins/analysis
KW - Endonucleases/analysis
KW - Female
KW - Humans
KW - Immunohistochemistry/methods
KW - Liver Neoplasms/metabolism
KW - Male
KW - Middle Aged
KW - Observer Variation
U2 - 10.1016/j.prp.2020.152826
DO - 10.1016/j.prp.2020.152826
M3 - Journal article
C2 - 32008866
VL - 216
JO - Pathology, Research and Practice
JF - Pathology, Research and Practice
SN - 0344-0338
IS - 3
M1 - 152826
ER -
ID: 256578435